Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson 1Q

Revenues up 9% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson

1Q Revenues: $17.5 billion  (+9%)

1Q Earnings: $3.5 billion (-11%)

Comments: Pharmaceutical sales were $6.8 billion, up 10%. Primary contributors to growth were Invega, Sustenna/Xeplion, Stelara, Simponi, Remicade, Prezista, and sales of recently launched products. Consumer sales were $3.7 billion, up 2%. Medical Devices and Diagnostics sales were $7.1 billion, up 10%. Domestic sales increased 11% and international sales increased 6%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business, which contributed 6% to operational sales growth. Earnings included after-tax items of approximately $0.6 billion, primarily related to litigation expenses, as well as integration and costs for the Synthes acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters